What Will Part D Prices Look Like in 2007?

Big Pharma companies say its too early to tell what prices will look like under Medicare Part D next year. That is in part because they can't be sure yet what prices they will get in 2006. That won't be clear until claims are reconciled this fall.

The question came up on almost all the Big Pharma company second quarter earnings calls: What will happen to prices under Medicare Part D in 2007? As has become abundantly clear, most pharma companies saw a net price increase from the transition to Part D this year, since more than six million Medicare beneficiaries previously receiving coverage under Medicaid (with mandatory rebates) transferred to the new program. (See "Big Pharma’s Secret Weapon," The RPM Report, July/August 2006 Also see "Big Pharma's Secret Weapon: Medicare Starts to Pay Off-Quietly" - Pink Sheet, 1 July, 2006..)

But what happens next year? Managed care plans offering Part D now have actual enrollment, and a handful of plans—led...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet

COVID-19 mRNA Vaccine Labels Now Quantify Myocarditis Risk, But ACIP Wants Other Changes

 
• By 

New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”